Glycosylation-dependent opsonophagocytic activity of staphylococcal protein A antibodies.

Antibodies may bind to bacterial pathogens or their toxins to control infections, and their effector activity is mediated through the recruitment of complement component C1q or the engagement with Fcγ receptors (FcγRs). For bacterial pathogens that rely on a single toxin to cause disease, immunity correlates with toxin neutralization. Most other bacterial pathogens, including Staphylococcus aureus, secrete numerous toxins and evolved multiple mechanisms to escape opsonization and complement killing. Several vaccine candidates targeting defined surface antigens of S. aureus have failed to meet clinical endpoints. It is unclear that such failures can be solely attributed to the poor selection of antibody targets. Thus far, studies to delineate antibody-mediated uptake and killing of Gram-positive pathogens remain extremely limited. Here, we exploit 3F6-hIgG1, a human monoclonal antibody that binds and neutralizes the abundant surface-exposed Staphylococcal protein A (SpA). We find that galactosylation of 3F6-hIgG1 that favors C1q recruitment is indispensable for opsonophagocytic killing of staphylococci and for protection against bloodstream infection in animals. However, the simple removal of fucosyl residues, which results in reduced C1q binding and increased engagement with FcγR, maintains the opsonophagocytic killing and protective attributes of the antibody. We confirm these results by engineering 3F6-hIgG1 variants with biased binding toward C1q or FcγRs. While the therapeutic benefit of monoclonal antibodies against infectious disease agents may be debatable, the functional characterization of such antibodies represents a powerful tool for the development of correlates of protection that may guide future vaccine trials.

<span class="Species">Staphylococcus aureus (MSSA, methicillin-sensitive S. aureus) and its antibiotic-resistant isolates (MRSA, methicillin-resistant S. aureus) persistently colonize the nasopharynx of 31% (MSSA) and 2% (MRSA) of the US population, respectively, while the remainder population is intermittently colonized (1, 2). Colonization is the key risk factor for invasive diseases, which manifest as skin and soft-tissue infections, osteomyelitis, pneumonia, septic arthritis, bacteremia, and endocarditis (3). In the United States, community-acquired disease is associated with 3.2 million (MSSA) and 238,000 (MRSA) clinical visits each year (4). Further, 359,000 MSSA and 101,000 MRSA cases of hospital-acquired infection occur, for 37 million hospital admissions (5). MRSA infection is associated with treatment failure and increased mortality (6). Several attempts to develop vaccines or immune therapeutics that prevent disease or improve the outcome of S. aureus infections have failed (7).

<span class="Species">S. aureus is a Gram-positive organism with a thick envelope, which, unlike most Gram-negative bacteria, cannot be lysed by complement and the membrane attack complex (7). Secreted Sbi and cell wall-bound SpA capture the fragment-crystallizable region of IgG (Fcγ) and thwart opsonization with S. aureus-specific antibodies. Sbi and SpA encompass two and five immunoglobulin-binding domains (IgBDs), respectively. Each IgBD binds to Fcγ of human IgG1, IgG2, and IgG4 (but not to IgG3) and of mouse IgG (IgG1, IgG2a, IgG2b, IgG2c, and IgG3) (8–11). SpA, but not Sbi, also binds the variant heavy chain of VH3 idiotypic IgM, IgG, IgD, and IgE (12–14). During infection, S. aureus releases SpA, which cross-links the variant heavy chains of VH3 clan B cell receptors (IgM) and triggers B cell proliferation and the secretion of VH3 clonal antibodies (15, 16). Released SpA diverts B cell development and blocks the production of pathogen-specific IgG (15, 16). Humans, guinea pigs, and mice fail to generate SpA-neutralizing antibodies (12, 16, 17). Thus, any therapeutic strategy involving S. aureus-specific antibody must address the SpA and Sbi defenses of staphylococci.

Earlier, we developed nontoxigenic <span class="Gene">SpAKKAA that no longer binds immunoglobulins (12) and isolated the mouse hybridoma monoclonal antibody 3F6 (3F6-mhIgG2a). This antibody binds the folded triple-helical structure of IgBDs and blocks ligand binding to SpA and Sbi. When administered to mice, 3F6-mhIgG2a protects animals against S. aureus bloodstream infection (11, 12, 18). In an effort to develop a therapeutic antibody, the complementarity-determining regions (CDRs) of 3F6-mhIgG2a were stitched into the VH and VL gene elements of a human IgG1 (hIgG1) antibody (18, 19) (Fig. 1). The new humanized 3F6 IgG1 antibody (3F6-hIgG1) improved the outcome of MRSA bloodstream infections in experimental animals (18, 19). Here, we use a combination of glycoengineering and site-directed mutagenesis to discern the effector functions of 3F6 therapeutic antibodies.

Fig. 1.

3F6-hIgG1 produced by HEK 293F cells protects mice against MRSA bloodstream infection. (A) Schematic of recombinant antibodies generated by swapping the complementarity determining regions (CDRs) of human VH1-idiotypic IgG1 with the CDRs of mouse hybridoma 3F6-mhIgG2a. Production in CHO-DG44 and HEK 293F cells yielded 3F6-hIgG1CHO and 3F6-hIgG1HEK, respectively. (B) Coomassie-stained gel of antibodies. nonred./red., nonreducing/reducing conditions, respectively. (C) Antibody binding to SpAKKAA measured by ELISA and reported as association constants (Ka; n = 3); A450, absorbance at 450 nm. (D) Antibodies 3F6-hIgG1CHO and 3F6- hIgG1HEK prevent the association of SpA to human IgG better than human IgG1 (hIgG1). Values were normalized to SpA interaction with human IgG in PBS (n = 3). (E and F) Animals (BALB/c) received PBS, human IgG1 (hIgG1), mouse hybridoma monoclonal antibody 3F6-mhIgG2a, 3F6- hIgG1CHO, or 3F6-hIgG1HEK prior to challenge with S. aureus MW2. Fifteen days post infection, kidneys (n = 16 to 20 from 2 independent experiments) were removed and either ground for enumeration of CFU per gram tissue (E) or fixed and stained for enumeration of internal abscesses (F). (G) Administration of 3F6-hIgG1HEK prior to infection promotes enhanced antistaphylococcal serum IgG responses. Sera (n = 3) of animals shown in E were tested for antibodies against the indicated S. aureus antigens. (H) Plasma concentration–time profile of antibodies following i.p. administration into BALB/c mice (n = 5). Data are presented as mean ± SEM (C–H). Significant differences were identified with the two-tailed Student’s t test (D and G) and one-way ANOVA with Kruskal–Wallis test (E and F; **P < 0.01; *P < 0.05; ns, not significant).

3F6-h<span class="Gene">IgG1 produced by HEK 293F cells protects mice against MRSA bloodstream infection. (A) Schematic of recombinant antibodies generated by swapping the complementarity determining regions (CDRs) of human VH1-idiotypic IgG1 with the CDRs of mouse hybridoma 3F6-mhIgG2a. Production in CHO-DG44 and HEK 293F cells yielded 3F6-hIgG1CHO and 3F6-hIgG1HEK, respectively. (B) Coomassie-stained gel of antibodies. nonred./red., nonreducing/reducing conditions, respectively. (C) Antibody binding to SpAKKAA measured by ELISA and reported as association constants (Ka; n = 3); A450, absorbance at 450 nm. (D) Antibodies 3F6-hIgG1CHO and 3F6- hIgG1HEK prevent the association of SpA to human IgG better than human IgG1 (hIgG1). Values were normalized to SpA interaction with human IgG in PBS (n = 3). (E and F) Animals (BALB/c) received PBS, human IgG1 (hIgG1), mouse hybridoma monoclonal antibody 3F6-mhIgG2a, 3F6- hIgG1CHO, or 3F6-hIgG1HEK prior to challenge with S. aureus MW2. Fifteen days post infection, kidneys (n = 16 to 20 from 2 independent experiments) were removed and either ground for enumeration of CFU per gram tissue (E) or fixed and stained for enumeration of internal abscesses (F). (G) Administration of 3F6-hIgG1HEK prior to infection promotes enhanced antistaphylococcal serum IgG responses. Sera (n = 3) of animals shown in E were tested for antibodies against the indicated S. aureus antigens. (H) Plasma concentration–time profile of antibodies following i.p. administration into BALB/c mice (n = 5). Data are presented as mean ± SEM (C–H). Significant differences were identified with the two-tailed Student’s t test (D and G) and one-way ANOVA with Kruskal–Wallis test (E and F; **P < 0.01; *P < 0.05; ns, not significant).

Results

3F6-hIgG1HEK, but Not 3F6-hIgG1CHO, Protects Mice Against S. aureus Bloodstream Infection.

Two cell lines, <span class="Chemical">CHO-DG44 and HEK-293F, were used to produce humanized anti-SpA antibodies. The corresponding antibodies, designated 3F6-hIgG1CHO and 3F6-hIgG1HEK (Fig. 1), were affinity-purified, and their integrity and homogeneity were documented by Coomassie-stained SDS/polyacrylamide gel electrophoresis (SDS/PAGE) under reducing and nonreducing conditions (Fig. 1). Both antibodies exhibited a similar affinity for SpAKKAA (Fig. 1) and displaced interactions between hIgG and SpA more effectively than hIgG1 (Fig. 1). When incubated with staphylococci, ∼13,400 molecules of antibody (3F6-hIgG1CHO or 3F6-hIgG1HEK) were found to coat each bacterial cell (). To assess their therapeutic activity, 3F6-hIgG1CHO and 3F6-hIgG1HEK were injected into BALB/c mice prior to i.v. challenge with the methicillin-resistant S. aureus isolate MW2, herein referred to as MRSA (Fig. 1 ). Animals treated with PBS and hIgG1 or with 3F6-mhIgG2a served as negative and positive control groups, respectively. Animals were killed 15 d post challenge. Disease was assessed by visual inspection of intact kidneys for areas with pus collection (), enumeration of colony-forming units (CFU) following plating of kidney tissues (Fig. 1), and enumeration of abscess lesion using H&E-stained kidney tissue sections (Fig. 1). Animals that received 3F6-mhIgG2a or 3F6-hIgG1HEK harbored fewer abscess lesions ( and Fig. 1) and reduced bacterial loads in renal tissues (Fig. 1) compared to animals that received PBS or hIgG1. The protective activities of 3F6-mhIgG2a and 3F6-hIgG1HEK were indistinguishable. Surprisingly, 3F6-hIgG1CHO administration afforded no protection and behaved similarly to PBS and hIgG1 controls ( and Fig. 1 ). Earlier reports demonstrate that successful neutralization of SpA blocks its B cell superantigen activity, resulting in the production of polyclonal antibodies against staphylococcal antigens (12, 18). Animal sera collected postchallenge were used to measure IgG titers against a staphylococcal antigen matrix encompassing 17 purified antigens (Fig. 1). Immunization with 3F6-hIgG1HEK or reference control 3F6-mhIgG2a elicited antibody production against the virulence determinants ClfA, IsdB, Coa, and vWbp as well as surface antigens ClfB, SasI, and FnBPA; this was not observed in animals treated with 3F6-hIgG1CHO, PBS, or hIgG1 (Fig. 1 and ). i.p. injection of 3F6-hIgG1CHO and 3F6-hIgG1HEK into mice was associated with a typical biexponential plasma concentration–time profile, revealing similar half-lives (Fig. 1). In agreement with this observation, 3F6-hIgG1CHO and 3F6-hIgG1HEK displayed similar binding affinities to the human neonatal Fc receptor (FcRn) in vitro (). Together these data indicate that 3F6-hIgG1HEK, but not 3F6-hIgG1CHO, protects mice against MRSA infection, and the difference in protection is not caused by a reduced half-life of 3F6-hIgG1CHO. To determine when 3F6-hIgG1HEK protected animals during infection, antibodies were transferred 24 h before or 24 h after infection, and animals were killed 5 and 15 d following bloodstream inoculation with MRSA (). Staphylococci disseminate to organs and begin to replicate into foci that mature to H&E-stainable lesions over 5 d. Prior administration of 3F6-hIgG1HEK caused a significant reduction in bacterial loads on day 5 compared to mock (1.72 × 108 ± 2.43 × 107 vs. 8.61 × 107 ± 1.40 × 107 CFU/g kidney) but no reduction in the number of lesions (). This 50% reduction in bacterial loads supports the notion that the antibody promotes opsonophagocytic killing. As expected, on day 15 post infection, both bacterial loads and abscess lesions were significantly reduced (). As neutralization of the B cell superantigen activity of SpA elicits a broad antibody response (Fig. 1), the continued clearance of bacteria is likely due to both monoclonal and polyclonal antibodies. Administration of 3F6-hIgG1HEK post infection also protected animals, but significant differences were only observed on day 15 for bacterial loads in kidneys ().

Fc-Galactosylation Is Required for the Protective Activity of 3F6 Antibodies.

Antibody-mediated effector functions are modu<span class="Gene">lated by Fc N-glycosylation (20). Asn297 is modified with a heptasaccharide core (GlcNAc2Man3GlcNAc2) and variable additions of fucose (F), galactose (G), and sialic acid (S). Binding to the immobilized Erythrina crista-galli lectin (ECL) and Sambucus nigra agglutinin (SNA) suggested that 3F6-hIgG1HEK has higher galactose and sialic acid contents than 3F6-hIgG1CHO (). For a more thorough analysis, glycans were released from antibody preparations and subjected to matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry to reveal a complex carbohydrate content profile with peaks corresponding to the fucosylated nongalactosylated (G0F), monogalactosylated (G1F), and digalactosylated N-glycans (G2F; Fig. 2). The G1F and G2F glycoforms were more abundant in the 3F6-hIgG1HEK preparation compared to the 3F6-hIgG1CHO preparation (Fig. 2 ). Quantification of glycoforms revealed that 3F6-hIgG1HEK contains two times and nine times more galactosyl and sialic acid residues, respectively, than 3F6-hIgG1CHO (Fig. 2 and ). To determine whether the Fc glycan structure is a key determinant for protection against S. aureus bloodstream infection, we used enzymes to transfer or remove galactose, yielding 3F6-hIgG1CHO-Gal or 3F6-hIgG1HEK-deGal. Neuraminidase was used to generate 3F6-hIgG1CHO-deSia and 3F6-hIgG1HEK-deSia lacking sialic acid. None of these treatments altered the integrity of antibodies (). These glycoforms bound SpAKKAA with similar affinities (Table 1 and ). Lectin binding assays confirmed the galactosylation, degalactosylation, or desialylation modifications of antibodies (). Animals were injected intraperitoneally with the five test antibodies, 3F6-hIgG1CHO, 3F6-hIgG1CHO-Gal, 3F6-hIgG1HEK, 3F6-hIgG1HEK-deGal, or 3F6-hIgG1HEK-deSia, and then challenged by i.v. inoculation of MRSA while monitoring body weight changes over 14 d (Fig. 2). On day 15, animals were euthanized and renal tissues examined for bacterial load and abscess formation (Fig. 2 ). As shown earlier, treatment with 3F6-hIgG1HEK but not human IgG1 and 3F6-hIgG1CHO reduced MRSA load as well as abscess formation (Fig. 2 ). Sialic acid modification (3F6-hIgG1HEK-deSia) is not required for this protective activity, while galactosylation is indispensable, as demonstrated by the loss of protection upon treatment of animals with 3F6-hIgG1HEK-deGal and by the gain of protection upon passive administration with 3F6-hIgG1CHO-Gal (Fig. 2 ). To unambiguously identify the Fc glycan structure responsible for protection against MRSA bloodstream infection, we used a chemoenzymatic method for glycan remodeling by first deglycosylating 3F6-hIgG1CHO and 3F6-hIgG1HEK with Endo-S2 and, second, transferring presynthesized glycan en bloc from activated glycan oxazoline in an EndoS2-D184M–dependent manner (21–24). Four antibodies, 3F6-hIgGHEK-G0F, 3F6-hIgGHEK-G1F, 3F6-hIgGHEK-G2F, and 3F6-hIgGCHO-G2F, with highly homogeneous and well-defined glycan profiles, were synthesized and tested for integrity and binding to SpAKKAA ( and Table 1). When injected in animals, both digalactosylated antibodies, 3F6-hIgGHEK-G2F and 3F6-hIgGCHO-G2F, protected animals from MRSA challenge (Fig. 2 ). Monogalactosylated 3F6-hIgGHEK-G1F protected equally well. However, no protection was observed for the G0F glycoform 3F6-hIgG1HEK-G0F (Fig. 2 ). 3F6 antibody-mediated protection correlated with the development of a broader immune response against multiple bacterial molecules as monitored with the MRSA antigen matrix (Fig. 2 ). In conclusion, galactosylation is key to the protective attribute of 3F6-hIgG1 in vivo.

Fig. 2.

3F6-hIgG1 glycoforms are determinants of therapeutic efficacy against MRSA. (A) MALDI-TOF mass spectra of 3F6-hIgG1CHO (Left) and 3F6-hIgG1HEK (Right) with glycan structures: fucose (brown), N-acetylglucosamine (blue), mannose (green), and galactose (yellow). (B) Quantification of glycoforms from mass spectra shown in A. (C–J) Animals (BALB/c) received test antibodies as indicated before challenge with S. aureus MW2. Weight (n = 10) was recorded daily and reported as percentage of initial weight (C and F). Fifteen days post infection, kidneys and sera were obtained during necropsy as described in Fig. 1; kidneys (n = 16 to 20 from 2 independent experiments) were examined for CFU (D and G) and internal abscesses (E and H), and animal sera (n = 6 to 10) were tested for antibodies against the indicated S. aureus antigens (I and J). Data are presented as mean ± SEM (C–J). Significant differences were identified with one-way ANOVA with Kruskal–Wallis test (D–G) and the two-tailed Student’s t test (I and J; **P < 0.01; *P < 0.05; ns, not significant).

Table 1.

Association constants for the binding of glycoengineered 3F6-hIgG1 to ligands measured by ELISA

3F6-hIgG1CHO
Ligand	Ka, M−1	WT	Gal	deSia	G2F
SpAKKAA	1010	2.54 ± 0.46	2.74 ± 0.23	2.85 ± 0.33	1.93 ± 0.13
Human C1q	106	4.91 ± 0.24	21.7 ± 1.71	5.50 ± 0.15	51.1 ± 6.57
Mouse C1q	106	8.87 ± 0.59	ND	ND	ND
3F6-hIgG1HEK
Ligand	Ka (M−1)	WT	deGal	deSia	G0F	G1F	G2F
SpAKKAA	1010	2.44 ± 0.52	2.86 ± 0.33	2.90 ± 0.32	2.34 ± 0.13	2.24 ± 0.16	1.93 ± 0.16
Human C1q	106	18.7 ± 4.0	4.0 ± 0.70	33.7 ± 3.74	6.94 ± 0.39	38.3 ± 3.58	55.0 ± 6.03
Mouse C1q	106	60.8 ± 7.44	ND	ND	ND	ND	ND

WT, wild-type; Gal, galactosylated; deSia, desialylated; ND, not determined; deGal, degalactosylated.

3F6-h<span class="Gene">IgG1 glycoforms are determinants of therapeutic efficacy against MRSA. (A) MALDI-TOF mass spectra of 3F6-hIgG1CHO (Left) and 3F6-hIgG1HEK (Right) with glycan structures: fucose (brown), N-acetylglucosamine (blue), mannose (green), and galactose (yellow). (B) Quantification of glycoforms from mass spectra shown in A. (C–J) Animals (BALB/c) received test antibodies as indicated before challenge with S. aureus MW2. Weight (n = 10) was recorded daily and reported as percentage of initial weight (C and F). Fifteen days post infection, kidneys and sera were obtained during necropsy as described in Fig. 1; kidneys (n = 16 to 20 from 2 independent experiments) were examined for CFU (D and G) and internal abscesses (E and H), and animal sera (n = 6 to 10) were tested for antibodies against the indicated S. aureus antigens (I and J). Data are presented as mean ± SEM (C–J). Significant differences were identified with one-way ANOVA with Kruskal–Wallis test (D–G) and the two-tailed Student’s t test (I and J; **P < 0.01; *P < 0.05; ns, not significant).

Association constants for the binding of glycoengineered 3F6-h<span class="Gene">IgG1 to ligands measured by ELISA

WT, wild-type; Gal, galactosy<span class="Gene">lated; deSia, desialy<span class="Gene">lated; ND, not determined; deGal, degalactosylated.

Protection by 3F6-hIgG1HEK in Mice Requires Complement.

<span class="Gene">C1q and FcγR interactions are both impacted by antibody galactosylation at Asn297 (25, 26). 3F6-hIgG1HEK displayed a greater affinity for both human and mouse C1q than 3F6-hIgG1CHO ( and Table 1). The differential glycosylation of CHO- and HEK-produced antibodies did not affect their binding affinities toward mouse FcγRs ( and Table 2). When examined using human FcγRs and their allotypes, 3F6-hIgG1CHO showed higher affinity toward activating receptors FcγRIIAR131, FcγRIIAH131, FcγRIIIAV158, and FcγRIIIAF158 and the inhibitory receptor FcγRIIB compared to 3F6-hIgG1HEK ( and Table 2). Both antibodies bound FcγRIA similarly ( and Table 2). Addition of galactose to CHO-produced antibody enhanced C1q binding, while removal of galactose from HEK-produced antibody reduced C1q binding ( and Table 1). 3F6-hIgG1CHO-G2F displayed the highest affinity toward C1q, comparable to that of 3F6-hIgG1HEK-G2F ( and Table 1). Glycoforms 3F6-hIgG1HEK-G1F and 3F6-hIgG1HEK-G2F displayed high affinities toward C1q ( and Table 1). Last, removal of sialic acid from 3F6-hIgG1HEK improved C1q binding slightly but had no impact on 3F6-hIgG1CHO activity ( and Table 1). This is unsurprising since sialic acid is only added to galactose residues; thus, only 0.45% of all CHO-produced antibodies were modified with sialic acid, compared to ∼4% of all HEK-produced antibodies (Fig. 2). To rule out the possibility that glycosylation may favor hexamer formation of antibodies (hexabodies), glycoforms of 3F6-hIgG1CHO and 3F6-hIgG1HEK antibodies were incubated with human serum. Hexabodies have been shown to bind C1q spontaneously and to activate complement in the absence of antigen (27). Complement activation assessed as increased C4d formation was only observed in the presence of heat-aggregated human IgG (HAG); neither 3F6 antibodies purified from CHO or HEK cells nor the chemoenzymatically modified variants elicited C4d production in serum ().

Table 2.

Association constants for the binding of 3F6-hIgG1CHO or 3F6-hIgG1HEK variants to ligands measured by ELISA

Ligand	Ka, M−1	WT 3F6-hIgG1CHO	3F6-hIgG1HEK
			WT	KA	LALA	afu
SpAKKAA	1010	2.54 ± 0.46	2.44 ± 0.52	2.85 ± 0.26	2.94 ± 032	2.50 ± 0.25
Human
C1q	106	4.91 ± 0.24	18.7 ± 4.0	1.37 ± 0.62	2.04 ± 1.18	5.97 ± 0.31
FcγRIA	108	7.66 ± 1.35	7.88 ± 1.51	7.86 ± 1.89	0.026 ± 0.086	5.83 ± 4.15
FcγRIIA (R131)	106	2.36 ± 0.39	1.53 ± 0.18	1.81 ± 0.18	0.99 ± 0.11	1.82 ± 0.25
FcγRIIA (H131)	106	1.75 ± 0.30	1.13 ± 0.16	1.23 ± 0.28	0.46 ± 0.029	1.51 ± 0.46
FcγRIIB	105	16.5 ± 1.92	9.25 ± 2.23	11.8 ± 1.55	8.38 ± 2.45	1.79 ± 0.88
FcγRIIIA (V158)	107	2.75 ± 0.50	2.31 ± 0.44	1.40 ± 0.12	0.26 ± 0.14	5.63 ± 0.94
FcγRIIIA (F158)	106	3.09 ± 0.33	1.97 ± 0.25	1.51 ± 0.34	0.85 ± 0.18	9.20 ± 0.14
Mouse
C1q	106	8.87 ± 0.59	60.8 ± 7.44	1.34 ± 0.30	2.91 ± 0.12	2.79 ± 0.16
FcγRI	108	1.77 ± 0.44	1.84 ± 0.48	3.97 ± 0.34	0.021 ± 0.078	0.92 ± 0.094
FcγRIIB	106	1.53 ± 0.26	1.61 ± 0.21	3.35 ± 0.48	1.60 ± 0.18	1.62 ± 0.12
FcγRIII	106	1.49 ± 0.16	1.69 ± 0.19	2.96 ± 0.40	1.72 ± 0.21	2.30 ± 0.34
FcγRIV	108	1.15 ± 0.20	1.35 ± 0.43	2.66 ± 0.88	0.09 ± 0.019	3.19 ± 0.38

WT, wild-type; KA, K322A substitution; LALA, L233A/L234A substitutions; afu, afucosylated.

Association constants for the binding of 3F6-h<span class="Gene">IgG1CHO or 3F6-h<span class="Gene">IgG1HEK variants to ligands measured by ELISA

WT, wild-type; KA, <span class="Mutation">K322A substitution; LALA, <span class="Mutation">L233A/L234A substitutions; afu, afucosylated.

Amino acids K322 and L233/L234 have been implicated in the interaction of antibody with <span class="Gene">C1q (28, 29). To further delineate the C1q requirement for the therapeutic activity of 3F6-hIgG1HEK antibodies, we generated variants 3F6-hIgG1HEK-KA and 3F6-hIgG1HEK-LALA with substitutions K322A and L233A/L234A, respectively (). These substitutions did not affect antigen binding, sialylation, fucosylation, or galactosylation ( and Table 2). Binding to both human and mouse C1q was significantly reduced for these two variants, with affinities even lower than that of 3F6-hIgG1CHO for human and mouse C1q ( and Table 2). 3F6-hIgG1HEK and the KA variant interacted similarly with recombinant human FcγRs, but the LALA variant was impaired for interaction with human FcγRIA and FcγRIIIAV158 ( and Table 2). The KA variant exhibited slightly higher affinity to all mouse FcγRs compared to 3F6-hIgG1HEK; the LALA variant interacted considerably less well with mouse FcγRI and FcγRIV ( and Table 2). When administered to animals, the KA and LALA variants failed to restore body weight or reduce bacterial burden and abscesses in tissues 15 d postinfection with MRSA, revealing an inability to clear bacteria (Fig. 3 ). The KA and LALA variants also failed to neutralize the B cell superantigen activity of SpA, as reflected by the lack of a broad neutralizing antibody response (). Collectively, these findings indicate that C1q recruitment may be key to the therapeutic activity of anti-MRSA antibodies.

Fig. 3.

Contribution of complement and FcγRs to 3F6-hIgG1HEK–mediated protection against MRSA bloodstream infection. (A–C) Animals (BALB/c; n = 10 from 2 independent experiments) received control hIgG1, 3F6-hIgG1HEK, 3F6-hIgG1HEK-KA, or 3F6-hIgG1HEK-LALA before challenge with S. aureus MW2. Disease was assessed as described in Fig. 1. (D–F) Animals (BALB/c; n = 10 from 2 independent experiments) were treated with control hIgG1, 3F6-hIgG1HEK, or 3F6-hIgG1HEK-afu antibodies prior to challenge with S. aureus MW2. Disease was assessed as described in Fig. 1. Data are presented as mean ± SEM. Significant differences were identified with one-way ANOVA with Kruskal–Wallis test (**P < 0.01; *P < 0.05). One of two repeats is shown.

Contribution of complement and FcγRs to 3F6-h<span class="Gene">IgG1HEK–mediated protection against MRSA bloodstream infection. (A–C) Animals (BALB/c; n = 10 from 2 independent experiments) received control hIgG1, 3F6-hIgG1HEK, 3F6-hIgG1HEK-KA, or 3F6-hIgG1HEK-LALA before challenge with S. aureus MW2. Disease was assessed as described in Fig. 1. (D–F) Animals (BALB/c; n = 10 from 2 independent experiments) were treated with control hIgG1, 3F6-hIgG1HEK, or 3F6-hIgG1HEK-afu antibodies prior to challenge with S. aureus MW2. Disease was assessed as described in Fig. 1. Data are presented as mean ± SEM. Significant differences were identified with one-way ANOVA with Kruskal–Wallis test (**P < 0.01; *P < 0.05). One of two repeats is shown.

FcγRs Contribute to the Therapeutic Activity of 3F6-hIgG1HEK.

Antibody interaction with FcγRs can be modu<span class="Gene">lated by fucosylation. Loss of fucosylation results in weaker and higher binding toward inhibitory and activating FcγRs, respectively (30). 3F6-hIgG1HEK is extensively fucosylated (Fig. 2), a modification that may not be optimal for FcγR-mediated activity. To test this possibility, afucosylated 3F6-hIgG1HEK (3F6-hIgG1HEK-afu) was produced by adding kifunensine to the culture medium in an effort to enrich for low-fucose glycoforms. 3F6-hIgG1HEK-afu retained its integrity and SpAKKAA binding (). Lectin-based assays confirm the low-level fucosylation and galactosylation of 3F6-hIgG1HEK-afu compared to 3F6-hIgG1HEK (). Binding to inhibitory receptor human FcγRIIB was reduced, and binding to activating receptors human FcγRIIIA (both alleles) and mouse FcγRIII and FcγRIV was enhanced ( and Table 2), thus effectively altering the activating-to-inhibitory (A/I) ratio of FcγRs (31). Importantly, 3F6-hIgG1HEK-afu displayed significantly reduced affinity for human and mouse C1q compared to fucosylated 3F6 (Table 2). In fact, 3F6-hIgG1HEK-afu interactions with C1q molecules were as weak as that of nontherapeutic 3F6-hIgG1CHO (Table 2). Nonetheless, when transferred to animals, 3F6-hIgG1HEK-afu controlled MRSA infection as reflected by the reduced weight loss, bacterial loads, and abscesses and the broad antibody responses against secreted antigens (Fig. 3 and ). Thus, we attribute the protective activity of 3F6-hIgG1HEK-afu in animals to its enhanced binding toward activating FcγRs. These results suggest that the therapeutic activity of 3F6-hIgG1HEK may be achieved both in complement- and FcγRs-dependent manners in vivo.

Both Complement and FcγRs Contribute to the OPK Activity of 3F6-hIgG1HEK in Human Blood.

In addition to capturing immunoglobulins in an <span class="Gene">SpA- and Sbi-dependent manner, S. aureus also exploits the host factors prothrombin and fibrinogen to induce the formation of fibrin agglutinates that shield bacteria from phagocytes. Secreted coagulases, Coa and vWbp, and surface-displayed ClfA are key factors involved in this process (32). Correlates of protection for vaccines are typically measured as the concentration of antibody able to induce opsonophagocytosis of a given pathogen by HL60 cells, i.e., human promyelocytic leukemia cells (33). Because this assay lacks hemostasis factors (prothrombin and fibrinogen), it is not adequate to evaluate the opsonophagocytic activity of antibodies against S. aureus. Earlier work developed a whole-blood assay whereby enumeration of S. aureus after 1 h incubation in freshly drawn anticoagulated blood is achieved by releasing bacteria from agglutinates upon treatment with the plasminogen activator streptokinase (32). Using this assay, 3F6-hIgG1HEK promoted killing of MRSA in human blood. As expected, pretreatment of blood with cytochalasin D, an inhibitor of actin polymerization and thus phagocytosis, abrogated 3F6-hIgG1HEK–mediated killing of MRSA in human blood (Fig. 4). Pretreatment of blood with C1 esterase inhibitor (C1-inh) that binds and inactivates C1r and C1s also prevented killing of bacteria in the presence of 3F6-hIgG1HEK antibodies. Antibody binding to C1q activates C1r and C1s to trigger the classical complement pathway and the activation of C3 and C5 (34). In agreement with a requirement for complement, neither the KA nor the LALA variant of 3F6-hIgG1HEK promoted opsonophagocytic killing. Nonetheless, afucosylated 3F6-hIgG1HEK with greatly reduced C1q binding and enhanced FcγR binding activity promoted the killing of MRSA in human blood (Fig. 4). Thus, in this opsonophagocytic assay optimized for coagulase-positive S. aureus, bacterial killing may be promoted by both effector functions of antibody.

Fig. 4.

3F6-hIgG1HEK employs both complement and FcγRs to promote opsonophagocytic killing in human blood. (A) S. aureus MW2 survival in human blood (n = 4) without or with cytochalasin D (−/+ CD). (B) S. aureus MW2 survival in human blood (n = 5) in absence or presence of complement inhibitor (−/+ C1 Inh). (C) Opsonophagocytic killing activities of antibody variants compared to hIgG1 and 3F6-hIgG1HEK toward S. aureus MW2 in human blood (n = 10). Data were plotted as the average ± SEM of CFUs after 60 min incubation in blood compared to CFUs of inoculum (set as 100%). Significant differences were identified with the two-tailed Student’s t test (*P < 0.05; **P < 0.01).

3F6-h<span class="Gene">IgG1HEK employs both complement and FcγRs to promote opsonophagocytic killing in human blood. (A) S. aureus MW2 survival in human blood (n = 4) without or with cytochalasin D (−/+ CD). (B) S. aureus MW2 survival in human blood (n = 5) in absence or presence of complement inhibitor (−/+ C1 Inh). (C) Opsonophagocytic killing activities of antibody variants compared to hIgG1 and 3F6-hIgG1HEK toward S. aureus MW2 in human blood (n = 10). Data were plotted as the average ± SEM of CFUs after 60 min incubation in blood compared to CFUs of inoculum (set as 100%). Significant differences were identified with the two-tailed Student’s t test (*P < 0.05; **P < 0.01).

Discussion

The discovery that serum from <span class="Disease">infected animals contains antibacterial activity was readily exploited in the early 20th century, principally against diphtheria toxin (35). Broader-spectrum drugs and antibiotics soon eclipsed serum therapy. To date, only a handful of therapeutic antibodies have been licensed for the prevention of infectious diseases (36). This is unlike the expanding number of mAbs for immune-mediated disorders and cancer (37). While target selection through Fab recognition is critical for success, disease amelioration is governed by the deployment of effector mechanisms mediated by the Fc regions of antibodies. Effector functions have been best characterized for anticancer antibodies for which the specific destruction of tumor cells or the enhancement of tumor-specific T cell immunity can be readily measured (38, 39). Interactions with FcγRs trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell mediated phagocytosis (ADCP) of tumor cells (38, 39). Interaction with C1q activates the classical complement pathway to promote the direct lysis of tumor cells upon insertion of the membrane attack complex (i.e., complement-dependent cytotoxicity [CDC]) or the covalent deposition of opsonins such as C3b onto the cell surface. Complement receptors on effector cells bind opsonized targets promoting complement-dependent cell-mediated cytotoxicity (CDCC) and complement-dependent cell-mediated phagocytosis (CDCP) (40, 41). The mode of action required for antibody-mediated elimination of bacterial pathogens is not as well understood.

We have shown earlier that protection against S. <span class="Disease">aureus disease by candidate 3F6-hIgG1 correlates with the ability of this antibody to bind multiple IgBDs of SpA and block further interactions with Fcγ and Fab VH3 domains of Ig (11). However, CHO cell-produced 3F6-hIgG1CHO displayed no therapeutic activity in a mouse model of MRSA infection. This was unlike 3F6-hIgG1 produced in HEK 293F cells. CHO cell is a nonhuman mammalian cell line, often selected for the commercial production of therapeutic proteins owing to high productivity and low operating costs (42). Lack of antibody activity could not be attributed to a reduced half-life in vivo or an inability to form immune complexes with SpA. Rather, the defect correlated with the low abundance of galactosylated antibodies in CHO cells compared to HEK 293 cells (∼30% vs. ∼58% G0F, ∼48% vs. ∼28% G1F, and ∼11% vs. ∼4% G2F) (43–45), suggesting altered Fc-mediated effector activity (25, 26, 46). Enzymatic addition of galactosyl residues enhanced the therapeutic activity of 3F6-hIgG1CHO while enzymatic degalactosylation reduced the therapeutic activity of 3F6-hIgG1HEK. Chemoenzymatic glycoengineering further demonstrated therapeutic activity for G1F and G2F glycoforms of 3F6-hIgG1 but not for G0F.

Both the length and substitutions of <span class="Chemical">N-glycans at Asn297 have been shown to affect the stability of the polypeptide loop containing Asn297 and influence binding with FcγRs and C1q (25, 26, 46). Increased galactosylation of 3F6-hIgG1 and removal of sialic acid residues enhanced both human and mouse C1q binding in vitro without altering binding to mouse FcγRs. Overall, the activating-to-inhibitory ratio (calculated by dividing the affinity of antibody for activating receptors by the affinity for inhibitory receptors) was similar between 3F6-hIgG1CHO and 3F6-hIgG1HEK. These in vitro data support the notion that the therapeutic activity of galactosylated 3F6-hIgG1 is C1q-dependent. In agreement with this model, antibodies with amino acid substitutions L233A/L234A or K322A displayed reduced C1q binding and failed to protect animals from MRSA bloodstream infection. Of note, substitution K322A did not affect interactions with FcγRs at all.

<span class="Gene">SpA is extremely abundant on the surface of S. aureus, with ∼13,400 molecules per cell. It is thus reasonable to hypothesize that the proximal binding of multiple 3F6-hIgG1-G2K molecules recruits C1q to activate the classical pathway of complement, which converges in the assembly of C3 convertase (C4b2a). C3 convertase cleaves C3 into C3a and C3b; C3b can be covalently linked to the staphylococcal surface (opsonization) while C3a acts as a chemoattractant for phagocytes. High local concentrations of C3b activate the C5 convertase, resulting in the production of the C5a chemoattractant and C5b, whose surface deposition promotes membrane attack complex formation (47). The thick peptidoglycan of S. aureus provides intrinsic resistance against CDC. Thus, it is likely that C3a and C5a production promote immune cell recruitment and degranulation while C3b likely promotes CDCP. In agreement with this notion, inactivation of complement C1r/C1s molecules or addition of cytochalasin D in whole human blood prevented killing of MRSA in the presence of 3F6-hIgG1. Interestingly, S. aureus deploys a vast array of secreted factors to block complement activation (reviewed in ref. 48). SpA and Sbi IgBDs capture antibodies in a manner that prevents further C1q but not FcγR binding (48). Sbi carries two additional domains that associate with C3 and factor H (fH) to inhibit the alternative pathway (48). In addition, staphylococcal complement inhibitor (SCIN) and homologs SCIN-B and SCIN-C inhibit C3 convertase (C3bBb). SCIN factors are encoded by many, but not all, human clinical isolates, and associate with human C3 convertase but not with other vertebrate convertases (48). Extracellular fibrinogen-binding protein (Efb) and its less conserved homolog, extracellular complement-binding protein (Ecb), bind C3d, a cleavage product of C3b that activates innate and adaptive responses by binding to complement receptor 2 (CR2). Efb and Ecb also inhibit mouse and human C3bBb and C5 convertases while Ecb facilitates fH’s activity (48). Staphylokinase associates with human plasminogen to cleave many factors, including C3b and iC3b, on bacterial surfaces (48).

Our findings suggest that 3F6-h<span class="Gene">IgG1HEK may also engage FcγRs as long as fucosylation of N-glycans is prevented. This is in agreement with the notion that fucosylation favors interactions with C1q and inhibitory FcγRs while weakening interactions with activating FcγRs (30). CRs and FcγRs are coexpressed on immune cells and engage in cross-talk activities. For example, C5a–C5aR interaction up-regulates the expression of activating FcγRs (FcγRIII and FcγRIV) and down-regulates the expression of inhibitory FcγRIIB (49, 50). Thus, in vivo, the immediate effect of 3F6-hIgG1HEK may be the rapid and strong activation of complement; subsequent C–CR interactions such as C5a–C5aR may lead to an increased A/I ratio that may tip the threshold activation of FcγRs by 3F6-hIgG1HEK.

In conclusion, our work suggests that antibodies against <span class="Species">S. aureus can be improved to achieve greater therapeutic activity, especially against hard-to-treat recurrent or persistent <span class="Disease">infections caused by antibiotic-resistant strains. Importantly, a better understanding of effector functions and of pathways leading to pathogen clearance by antibodies can be exploited to define correlates of protection for candidate vaccines.

Materials and Methods

Detailed information describing materials and methods is provided in .

Bacterial Strains, Mammalian Cell Lines and Growth Media.

Community-acquired <span class="Chemical">methicillin-resistant S. aureus USA400 (MW2) was grown in tryptic soy broth or agar at 37 °C. Suspension serum-free adapted FreeStyle 293-F cells (herein referred as HEK-293F cells) were cultured in FreeStyle 293 Expression Medium (Life Technologies) and maintained in a 5% CO2 humidified incubator at 37 °C. Kifunensine (Abcam), a small-molecule inhibitor of the enzyme α-mannosidase I, was added directly to FreeStyle 293 Expression Medium at a final concentration of 200 ng/mL (51–53).

Construction, Expression, and Purification of Recombinant 3F6-hIgG1 and Variant Antibodies.

The clone encoding 3F6-h<span class="Gene">IgG1 was as described earlier (18, 19). Briefly, plasmid encoding 3F6-hIgG1 was generated by swapping the coding sequences of the heavy- and light-chain genes of the mouse monoclonal antibody 3F6-mhIgG2a (54) into the expression vector pVITRO1-102.1F10-IgG1/λ (Addgene, no. 50366). This construct served as a template for further mutagenesis. Primers 5′ TGA​AGC​CGC​CGG​GGG​ACC​GT CAGTCTTCCT 3′ and 5′ CCC​GGC​GGC​TTC​AGG​TGC​TGG​GCA​CGG​TG 3′ were used to generate the LALA variant, and primers 5′ TGCGCCGTCTCCAAC AAAGCCCTCCCA 3′ and 5′ GAC​GGC​GCA​CTT​GTA​CTC​CTT​GCC​AT 3′ were used to generate the KA variant by site-directed mutagenesis as described earlier (28). All new plasmids were transfected into HEK-293F cells using polyethylenimine (55). Candidate transfectants were selected using hygromycin B (400 μg/mL) and expanded in TripleFlask Cell Culture Flasks (Thermo Fisher). 3F6-hIgG1CHO was produced using the dihydrofolate reductase-deficient mutant Chinese hamster ovary cell line DG44 as described earlier (19). Antibodies were affinity-purified from supernatants of expanded cultures on protein A-Sepharose (Sigma) and dialyzed to PBS as described earlier (11).

Animal Experiments.

BALB/c <span class="Species">mice (6 to 7 wk of age) were obtained from Jackson Laboratory. For passive immunization studies, animals were injected into the peritoneum with 5 mg/kg of indicated antibody 24 h before or 24 h after challenge. For challenge with S. aureus, animals were anesthetized with a mix of ketamine/xylazine (100 and 20 mg/kg). Cultures of USA400 (MW2) were grown to an absorbance at 600 nm of 0.42, and bacteria were washed in PBS once and adjusted to a suspension of 6.5 × 107 CFU/mL (colony forming unit). A total of 100 μL of this suspension was injected into the periorbital venous plexus of anesthetized animals (groups of 10 to 20). Animals were monitored for clinical signs of disease and weighed daily for 14 d. On day 15, mice were killed by carbon dioxide inhalation and necropsied to remove kidneys. Surface abscesses visible on intact kidneys were enumerated. One kidney per animal was fixed in 4% formalin for 24 h at room temperature; tissues were embedded in paraffin, thin-sectioned, stained with hematoxylin/eosin, and inspected by light microscopy to visualize and enumerate internal abscess lesions. The second kidney was weighed, homogenized, serially diluted, and plated on agar to count bacterial burden in tissues (CFU per gram of tissue). To measure the half-life of test antibodies, mice (groups of five) were injected into the peritoneal cavity with antibodies (5 mg/kg of body weight). After 1 and 4 h and after 1, 2, 3, 7, 13, 16, 23, and 28 d, periorbital venous blood was obtained and plasma samples analyzed by ELISA. Plasma antibody concentrations were calculated using a standard curve of 3F6-hIgG1HEK and 3F6-hIgG1CHO diluted in mouse plasma at a range of 1 to 500 ng/mL. Half-lives were calculated using Nt = N0 (1/2)t/t1/2, where N0 is the highest concentration of 3F6 antibodies, N(t) is the nondecayed concentration at time t, and t1/2 is the half-life of the decaying concentration.

Ethics Statement.

Experiments with blood from <span class="Species">human volunteers were performed with a protocol that was reviewed, approved, and supervised by the University of Chicago's Institutional Review Board (IRB). All <span class="Species">mouse experiments were performed in accordance with the institutional guidelines following experimental protocol review and approval by the Institutional Biosafety Committee (IBC) and the Institutional Animal Care and Use Committee (IACUC) at the University of Chicago.